Table 1.
Clinical and pathological characteristics of the study population.
| N | % | |
|---|---|---|
| Patients | 542 | 100 |
| Breast tumors | 564 | 100 |
| Age (median) (Range) |
62.1 (21.3–88.6) |
|
| BMI (median) (Range) |
24.2 (16.4–44.9) |
|
| Affected breast | ||
| Right | 276 | 48.9 |
| Left | 288 | 51.1 |
| Menopausal status | ||
| Premenopausal | 84 | 15.4 |
| Postmenopausal | 458 | 84.5 |
| Histological type | ||
| Ductal (NST) | 460 | 81.6 |
| Lobular | 79 | 14.0 |
| Other | 25 | 4.4 |
| Histopathological size (in mm, median) (Range) |
12 (1.5–40) |
|
| Pathological T stage | ||
| T1 | 554 | 98.2 |
| T2 | 10 | 1.8 |
| Tumor grade | ||
| 1 | 211 | 37.4 |
| 2 | 225 | 39.9 |
| 3 | 128 | 22.7 |
| Receptor-based subtype | ||
| ER + PR + HER2− | 425 | 75.3 |
| ER + PR + HER2+ | 40 | 7.1 |
| ER − PR − HER2− | 34 | 6.0 |
| ER − PR − HER2+ | 14 | 2.4 |
| Pathological lymph node status | ||
| N0 | 449 | 82.8 |
| N1 | 81 | 14.9 |
| N2 | 3 | 0.5 |
| Nx | 9 | 1.6 |
BMI, body mass index; NST, no specific type; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; Nx, no axillary staging.